Sanofi licenses ADEL’s tau-targeting Alzheimer’s drug for $80M upfront

In its second deal this week, Sanofi is spending $80 million upfront to license an Alzheimer’s drug candidate developed by the South Korean biotech ADEL. The French drugmaker will get global rights to ADEL-Y01, a ...